Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700149 · ClinicalTrials.gov registry record
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
A clinical trial of Nodal Marginal Zone Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG).
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT05700149 is a study of Nodal Marginal Zone Lymphoma that is actively recruiting participants, run by International Extranodal Lymphoma Study Group (IELSG). The registered enrollment target is 300 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT05700149, a study of Nodal Marginal Zone Lymphoma, is actively recruiting participants, sponsored by International Extranodal Lymphoma Study Group (IELSG).
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
Conditions Studied
Study Locations (20)
MI
- IRCCS Ospedale San Raffaele - Milan
- IEO Istituto Europeo di Oncologia - Milan
- ASST Grande Ospedale Metropolitano Niguarda - Milan
Other
- Hematology Center after Prof. Yeolyan - Yerevan
- University Hospital Centre Zagreb - Zagreb
Florida
- University of Miami - Miami
New York
- Weill Cornell Medical - New York
AL
- AO SS Antonio e Biagio e C. Arrigo - Alessandria
BA
- Istituto Tumori "Giovanni Paolo II" I.R.C.C.S. - Bari
BG
- ASST Papa Giovanni XXIII - Bergamo
BS
- ASST degli Spedali Civili di Brescia - Brescia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05700149
The ClinicalTrials.gov registry entry for NCT05700149 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Extranodal Lymphoma Study Group (IELSG), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nodal Marginal Zone Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT05700149 reports 20 study locations spanning 17 distinct geographic areas - top geographies include MI, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT05700149 about?
NCT05700149 is a clinical study titled "Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma". International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
What is the current status of trial NCT05700149?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-04-11. Estimated completion is 2026-12-31.
What conditions does trial NCT05700149 study?
This clinical trial studies the following conditions: Nodal Marginal Zone Lymphoma.
Who is sponsoring clinical trial NCT05700149?
This trial is sponsored by International Extranodal Lymphoma Study Group (IELSG), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05700149 being conducted?
This trial has 20 study locations across Florida, New York, AL, BA, BG. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nodal Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RECRUITING · Phase 2
-
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.